Compare NKTX & KINS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NKTX | KINS |
|---|---|---|
| Founded | 2015 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.4M | 205.7M |
| IPO Year | 2020 | 2013 |
| Metric | NKTX | KINS |
|---|---|---|
| Price | $2.93 | $16.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $11.33 | N/A |
| AVG Volume (30 Days) | ★ 960.2K | 120.0K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.18% |
| EPS Growth | 11.88 | ★ 94.59 |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | ★ $214,867,301.00 |
| Revenue This Year | N/A | $24.23 |
| Revenue Next Year | N/A | $18.05 |
| P/E Ratio | ★ N/A | $5.78 |
| Revenue Growth | N/A | ★ 38.50 |
| 52 Week Low | $1.63 | $13.08 |
| 52 Week High | $3.65 | $22.20 |
| Indicator | NKTX | KINS |
|---|---|---|
| Relative Strength Index (RSI) | 58.40 | 46.21 |
| Support Level | $1.88 | $14.13 |
| Resistance Level | $3.65 | $17.18 |
| Average True Range (ATR) | 0.28 | 0.99 |
| MACD | -0.02 | -0.13 |
| Stochastic Oscillator | 49.64 | 13.42 |
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
Kingstone Companies Inc offers property and casualty insurance products through its subsidiary engaged in writing business through retail and wholesale agents and brokers. Its products include Personal lines, Livery physical damage, and Others. It operates in single segment, property and casualty insurance. It derives substantially all of its revenue from KICO, including revenues from earned premiums, ceding commissions from quota share reinsurance, net investment income generated from its investment portfolio, and net realized gains and losses on investment securities.